Log in

NASDAQ:PHATPhathom Pharmaceuticals Stock Price, Forecast & News

+0.85 (+2.35 %)
(As of 08/12/2020 04:00 PM ET)
Today's Range
Now: $37.01
50-Day Range
MA: $32.95
52-Week Range
Now: $37.01
Volume60,300 shs
Average Volume78,168 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases. It also plans to initiate a Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PHAT



Sales & Book Value

Annual SalesN/A
Book Value$9.29 per share



Market Cap$1.07 billion
Next Earnings Date11/23/2020 (Estimated)
OptionableNot Optionable
+0.85 (+2.35 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHAT News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Phathom Pharmaceuticals (NASDAQ:PHAT) Frequently Asked Questions

How has Phathom Pharmaceuticals' stock been impacted by Coronavirus?

Phathom Pharmaceuticals' stock was trading at $34.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PHAT shares have increased by 6.5% and is now trading at $37.01.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Phathom Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Phathom Pharmaceuticals

When is Phathom Pharmaceuticals' next earnings date?

Phathom Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 23rd 2020.
View our earnings forecast for Phathom Pharmaceuticals

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals (NASDAQ:PHAT) issued its earnings results on Thursday, August, 6th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.02.
View Phathom Pharmaceuticals' earnings history

What price target have analysts set for PHAT?

4 brokerages have issued 1-year price objectives for Phathom Pharmaceuticals' stock. Their forecasts range from $32.00 to $45.00. On average, they expect Phathom Pharmaceuticals' share price to reach $37.00 in the next twelve months. This suggests that the stock has a possible downside of 0.0%.
View analysts' price targets for Phathom Pharmaceuticals

Has Phathom Pharmaceuticals been receiving favorable news coverage?

News articles about PHAT stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Phathom Pharmaceuticals earned a news impact score of -4.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about Phathom Pharmaceuticals

Who are some of Phathom Pharmaceuticals' key competitors?

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Vir Biotechnology (VIR), Clovis Oncology (CLVS), Goodrich Petroleum (GDP), Goodrich Petroleum (GDP), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Brainstorm Cell Therapeutics (BCLI), Cinemark (CNK) and CenterPoint Energy (CNP).

Who are Phathom Pharmaceuticals' key executives?

Phathom Pharmaceuticals' management team includes the following people:
  • Mr. David Socks, Co-Founder, Pres, CEO, Treasurer, Sec. & Director (Age 45)
  • Dr. Tadataka Yamada B.A., M.D., Ph.D., KBE, Co-Founder & Chairman (Age 73)
  • Dr. Azmi Nabulsi, Co-Founder & COO (Age 60)
  • Mr. Aditya Kohli Ph.D., Co-Founder & Chief Bus. Officer (Age 31)
  • Dr. Roger Ulrich, Co-Founder & Chief Scientific Officer

When did Phathom Pharmaceuticals IPO?

(PHAT) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Phathom Pharmaceuticals' stock symbol?

Phathom Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAT."

Who are Phathom Pharmaceuticals' major shareholders?

Phathom Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Frazier Management LLC (20.12%), Ensign Peak Advisors Inc (2.93%), Penn Mutual Asset Management LLC (0.30%), Hamilton Lane Advisors LLC (0.21%), Bank of New York Mellon Corp (0.15%) and California Public Employees Retirement System (0.11%). Company insiders that own Phathom Pharmaceuticals stock include Life Sciences Ix LP Frazier and Ra Capital Management, LP.
View institutional ownership trends for Phathom Pharmaceuticals

Which institutional investors are selling Phathom Pharmaceuticals stock?

PHAT stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, and UBS Group AG.
View insider buying and selling activity for Phathom Pharmaceuticals

Which institutional investors are buying Phathom Pharmaceuticals stock?

PHAT stock was purchased by a variety of institutional investors in the last quarter, including Ensign Peak Advisors Inc, Penn Mutual Asset Management LLC, Hamilton Lane Advisors LLC, California Public Employees Retirement System, BP PLC, Monarch Partners Asset Management LLC, Rockefeller Capital Management L.P., and Swiss National Bank. Company insiders that have bought Phathom Pharmaceuticals stock in the last two years include Life Sciences Ix LP Frazier, and Ra Capital Management, LP.
View insider buying and selling activity for Phathom Pharmaceuticals

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Phathom Pharmaceuticals' stock price today?

One share of PHAT stock can currently be purchased for approximately $37.01.

How big of a company is Phathom Pharmaceuticals?

Phathom Pharmaceuticals has a market capitalization of $1.07 billion. The company earns $-255,130,000.00 in net income (profit) each year or ($13.98) on an earnings per share basis. Phathom Pharmaceuticals employs 12 workers across the globe.

What is Phathom Pharmaceuticals' official website?

The official website for Phathom Pharmaceuticals is www.phathompharma.com.

How can I contact Phathom Pharmaceuticals?

Phathom Pharmaceuticals' mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The company can be reached via phone at 877-742-8466 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.